Low Dose Radiation Therapy Induces Long-Lasting Reduction of Pain and Immune Modulations in the Peripheral Blood - Interim Analysis of the IMMO-LDRT01 Trial.
chronic degenerative and inflammatory diseases
immune status
immunophenotyping
low dose radiation therapy (LDRT)
subjective pain level
x-rays
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
07
2021
accepted:
27
09
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
6
1
2022
Statut:
epublish
Résumé
The treatment of chronic inflammatory and degenerative diseases by low dose radiation therapy (LDRT) is promising especially for patients who were refractory for classical therapies. LDRT aims to reduce pain of patients and to increase their mobility. Although LDRT has been applied since the late 19th century, the immunological mechanisms remain elusive. Within the prospective IMMO-LDRT01 trial (NCT02653079) the effects of LDRT on the peripheral blood immune status, as well as on pain and life quality of patients have been analyzed. Blood is taken before and after every serial irradiation with a single dose per fraction of 0.5Gy, as well as during follow-up appointments in order to determine a detailed longitudinal immune status by multicolor flow cytometry. Here, we report the results of an interim analysis of 125 patients, representing half the number of patients to be recruited. LDRT significantly improved patients' pain levels and induced distinct systemic immune modulations. While the total number of leukocytes remained unchanged in the peripheral blood, LDRT induced a slight reduction of eosinophils, basophils and plasmacytoid dendritic cells and an increase of B cells. Furthermore, activated immune cells were decreased following LDRT. Especially cells of the monocytic lineage correlated to LDRT-induced improvements of clinical symptoms, qualifying these immune cells as predictive biomarkers for the therapeutic success. We conclude that LDRT improves pain of the patients by inducing systemic immune modulations and that immune biomarkers could be defined for prediction by improved patient stratification in the future.
Identifiants
pubmed: 34712229
doi: 10.3389/fimmu.2021.740742
pmc: PMC8546320
doi:
Substances chimiques
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT02653079']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
740742Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 Donaubauer, Becker, Weissmann, Fröhlich, Muñoz, Gryc, Denzler, Ott, Fietkau, Gaipl and Frey.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer KL declared a past co-authorship with authors UG and BF to the handling editor.
Références
Curr Rheumatol Rev. 2018;14(2):108-116
pubmed: 28875826
Radiat Oncol J. 2020 Sep;38(3):151-161
pubmed: 33012142
Immunobiology. 2015 Jun;220(6):833-44
pubmed: 25595536
FASEB J. 2009 Jan;23(1):164-71
pubmed: 18815360
Osteoarthritis Cartilage. 2017 Feb;25(2):209-215
pubmed: 28100423
PLoS One. 2017 Apr 26;12(4):e0176460
pubmed: 28445506
Blood. 2008 Sep 1;112(5):1570-80
pubmed: 18725575
Radiother Oncol. 2000 Mar;54(3):273-82
pubmed: 10738086
Ann Rheum Dis. 2010 Mar;69(3):483-9
pubmed: 19762361
Immunity. 2018 Feb 20;48(2):202-213
pubmed: 29466753
Int J Radiat Biol. 1999 Aug;75(8):995-1003
pubmed: 10465365
Int J Mol Sci. 2020 Aug 14;21(16):
pubmed: 32824064
Immunol Rev. 2009 May;229(1):114-25
pubmed: 19426218
Expert Rev Clin Immunol. 2019 May;15(5):541-552
pubmed: 30669892
Int J Mol Sci. 2016 Aug 11;17(8):
pubmed: 27529227
Front Immunol. 2018 Sep 18;9:1834
pubmed: 30279685
Strahlenther Onkol. 2015 Jan;191(1):1-6
pubmed: 25238992
Rep Pract Oncol Radiother. 2020 Mar-Apr;25(2):250-254
pubmed: 32140081
Front Immunol. 2019 May 22;10:1147
pubmed: 31191529
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33593828
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
Int J Radiat Biol. 2002 Aug;78(8):711-9
pubmed: 12194755
Osteoarthritis Cartilage. 2019 Mar;27(3):359-364
pubmed: 30453055
Curr Opin Rheumatol. 2011 Sep;23(5):471-8
pubmed: 21788902
Front Immunol. 2018 Oct 04;9:2279
pubmed: 30337927
Cancers (Basel). 2019 Apr 03;11(4):
pubmed: 30987228
Arthritis Rheumatol. 2020 Apr;72(4):557-564
pubmed: 31612614
Strahlenther Onkol. 2012 Dec;188(12):1108-13
pubmed: 23128898
Cell. 1996 May 3;85(3):307-10
pubmed: 8616886
Front Immunol. 2015 Nov 19;6:571
pubmed: 26635790
Strahlenther Onkol. 2019 Apr;195(4):285-288
pubmed: 30564845
Subcell Biochem. 2019;91:21-43
pubmed: 30888648
J Neuroimmunol. 2018 Sep 15;322:63-73
pubmed: 30049538
Med Oncol. 2018 Feb 10;35(3):36
pubmed: 29429058
Curr Med Res Opin. 2008 Aug;24(8):2283-94
pubmed: 18590608
Int J Radiat Biol. 2002 Jul;78(7):567-76
pubmed: 12079535
Front Med (Lausanne). 2020 May 19;7:195
pubmed: 32509794
Clin Exp Immunol. 2015 Jan;179(1):50-61
pubmed: 24730395
Strahlenther Onkol. 2020 Jun;196(6):569-575
pubmed: 31784803
Methods Mol Biol. 2019;1904:189-212
pubmed: 30539471
Methods Enzymol. 2020;632:389-415
pubmed: 32000906